Elevance Health (ELV) Stock Forecast & Price Target

Compare

2,859 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELV Analyst Ratings

Moderate Buy

10 Buy

4 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$385.14

▲(12.19% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $385.14 with a high forecast of $420.00 and a low forecast of $320.00. The average price target represents a 12.19% change from the last price of $343.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"270":"$270","427":"$427","309.25":"$309.3","348.5":"$348.5","387.75":"$387.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":420,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$420.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":385.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$385.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$320.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[270,309.25,348.5,387.75,427],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.99,335.0676923076923,342.1453846153846,349.2230769230769,356.3007692307692,363.3784615384615,370.4561538461538,377.5338461538462,384.6115384615385,391.6892307692308,398.7669230769231,405.8446153846154,412.9223076923077,{"y":420,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.99,332.38615384615383,336.7823076923077,341.17846153846153,345.5746153846154,349.97076923076924,354.36692307692306,358.76307692307694,363.15923076923076,367.5553846153846,371.95153846153846,376.3476923076923,380.74384615384616,{"y":385.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.99,327.37538461538463,326.76076923076926,326.1461538461539,325.53153846153845,324.91692307692307,324.3023076923077,323.6876923076923,323.07307692307694,322.45846153846156,321.84384615384613,321.22923076923075,320.6146153846154,{"y":320,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":400.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.19,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.77,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$420.00

Average Price Target$385.14

Lowest Price Target$320.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

George Hill

Deutsche Bank

$332→$320

Hold

-6.79%

Downside

Downgraded

12/19/25

Elevance Health downgraded to Hold from Buy at Deutsche BankElevance Health downgraded to Hold from Buy at Deutsche Bank

Ben Hendrix

RBC Capital

$392

Buy

14.19%

Upside

Reiterated

12/19/25

RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)

Erin Wright

Morgan Stanley

$359→$352

Hold

2.53%

Upside

Reiterated

12/18/25

Elevance Health price target lowered to $352 from $359 at Morgan StanleyElevance Health price target lowered to $352 from $359 at Morgan Stanley

Kevin Fischbeck

Bank of America Securities

$370→$385

Hold

12.15%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Argenx Se (NASDAQ: ARGX) and Sarepta Therapeutics (NASDAQ: SRPT)

Ryan Langston

TD Cowen

$380→$400

Buy

16.52%

Upside

Reiterated

11/26/25

Elevance Health: Strategic Positioning and Stability Drive Buy Rating with $400 Price Target

Ann Hynes

Mizuho Securities

$420→$400

Buy

16.52%

Upside

Reiterated

11/03/25

Elevance Health price target lowered to $400 from $420 at MizuhoElevance Health price target lowered to $400 from $420 at Mizuho

Lisa Gill

J.P. Morgan

$384→$394

Buy

14.77%

Upside

Reiterated

10/28/25

Elevance Health price target raised to $394 from $384 at JPMorganElevance Health price target raised to $394 from $384 at JPMorgan

David S Macdonald

Truist Financial

$400

Buy

16.52%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Gets a Buy from Truist Financial

Andrew Mok CFA

Barclays

$395→$385

Buy

12.15%

Upside

Reiterated

10/22/25

Barclays Sticks to Their Buy Rating for Elevance Health (ELV)

Stephen Baxter

Wells Fargo

$412→$403

Buy

17.39%

Upside

Reiterated

10/22/25

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

$400

Buy

16.52%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Cantor Fitzgerald

Jason Cassorla

Guggenheim

$398

Buy

15.93%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Guggenheim

Lance Wilkes

Bernstein

$445→$420

Buy

22.34%

Upside

Reiterated

10/16/25

Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Scott Fidel

Goldman Sachs

$343

Hold

-0.09%

Downside

Initiated

10/14/25

Elevance Health (ELV) Receives a Hold from Goldman Sachs

A.J. Rice

UBS

$425

Buy

23.80%

Upside

Reiterated

09/08/25

Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

George Hill

Deutsche Bank

$332→$320

Hold

-6.79%

Downside

Downgraded

12/19/25

Elevance Health downgraded to Hold from Buy at Deutsche BankElevance Health downgraded to Hold from Buy at Deutsche Bank

Ben Hendrix

RBC Capital

$392

Buy

14.19%

Upside

Reiterated

12/19/25

RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)

Erin Wright

Morgan Stanley

$359→$352

Hold

2.53%

Upside

Reiterated

12/18/25

Elevance Health price target lowered to $352 from $359 at Morgan StanleyElevance Health price target lowered to $352 from $359 at Morgan Stanley

Kevin Fischbeck

Bank of America Securities

$370→$385

Hold

12.15%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Argenx Se (NASDAQ: ARGX) and Sarepta Therapeutics (NASDAQ: SRPT)

Ryan Langston

TD Cowen

$380→$400

Buy

16.52%

Upside

Reiterated

11/26/25

Elevance Health: Strategic Positioning and Stability Drive Buy Rating with $400 Price Target

Ann Hynes

Mizuho Securities

$420→$400

Buy

16.52%

Upside

Reiterated

11/03/25

Elevance Health price target lowered to $400 from $420 at MizuhoElevance Health price target lowered to $400 from $420 at Mizuho

Lisa Gill

J.P. Morgan

$384→$394

Buy

14.77%

Upside

Reiterated

10/28/25

Elevance Health price target raised to $394 from $384 at JPMorganElevance Health price target raised to $394 from $384 at JPMorgan

David S Macdonald

Truist Financial

$400

Buy

16.52%

Upside

Reiterated

10/22/25

Elevance Health (ELV) Gets a Buy from Truist Financial

Andrew Mok CFA

Barclays

$395→$385

Buy

12.15%

Upside

Reiterated

10/22/25

Barclays Sticks to Their Buy Rating for Elevance Health (ELV)

Stephen Baxter

Wells Fargo

$412→$403

Buy

17.39%

Upside

Reiterated

10/22/25

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Sarah James

Cantor Fitzgerald

$400

Buy

16.52%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Cantor Fitzgerald

Jason Cassorla

Guggenheim

$398

Buy

15.93%

Upside

Reiterated

10/21/25

Elevance Health (ELV) Gets a Buy from Guggenheim

Lance Wilkes

Bernstein

$445→$420

Buy

22.34%

Upside

Reiterated

10/16/25

Bernstein Keeps Their Buy Rating on Elevance Health (ELV)

Scott Fidel

Goldman Sachs

$343

Hold

-0.09%

Downside

Initiated

10/14/25

Elevance Health (ELV) Receives a Hold from Goldman Sachs

A.J. Rice

UBS

$425

Buy

23.80%

Upside

Reiterated

09/08/25

Elevance Health: Positive Outlook with Strategic Pricing and Growth Opportunities Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month

xxx

Success Rate

17/28 ratings generated profit

Average Return

+1.45%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.71% of your transactions generating a profit, with an average return of +1.45% per trade.

3 Months

xxx

Success Rate

16/28 ratings generated profit

Average Return

+1.66%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.66% per trade.

1 Year

A.J. RiceUBS

Success Rate

22/30 ratings generated profit

Average Return

+16.96%

reiterated a buy rating 4 months ago

Copying A.J. Rice's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.96% per trade.

2 Years

xxx

Success Rate

26/30 ratings generated profit

Average Return

+39.72%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +39.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELV has received 23 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 385.14.

Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $3.15 with a range of $2.85 to $3.95. The previous quarter’s EPS was $6.03. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $49.71B with a range of $48.40B to $52.52B. The previous quarter’s sales results were $50.71B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 385.14.

What is ELV’s upside potential, based on the analysts’ average price target?

Elevance Health has 12.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELV a Buy, Sell or Hold?

Elevance Health has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.

What is Elevance Health’s price target?

The average price target for Elevance Health is 385.14. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $420.00 ,the lowest forecast is $320.00. The average price target represents 12.19% Increase from the current price of $343.3.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ELV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Elevance Health (ELV) Stock Forecast & Price Target

ELV Analyst Ratings

ELV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

ELV Analyst Recommendation Trends

ELV Financial Forecast

ELV Earnings Forecast

ELV Sales Forecast

ELV Stock Forecast FAQ

Detailed List of Analyst Forecasts